+59%, +42%, +22%: Our AI just called these healthcare winners

In a recent development, an AI model identified healthcare as the top-performing sector within the S&P 500. The sector experienced a remarkable 9.02% gain throughout October. In contrast, technology saw a decline, with the Philadelphia Semiconductor Index dropping 6.72% on Thursday alone. Despite this, healthcare stocks were notable for their strong performance, with three AI-selected holdings showing significant gains.

Amneal Pharmaceuticals, a mid-cap stock, emerged as the standout performer, surging 58.76% since April. The AI model purchased the stock at $12.90 on June 1, and it closed at $20.48 on Thursday. The company's second-quarter report, released on July 30, showed a 10% increase in net revenue to $796 million and a 17% rise in specialty sales.

Adjusted EBITDA climbed 12% to $206 million, and adjusted earnings per share grew by 20% to $0.30. Management also raised full-year guidance for revenue and adjusted EBITDA, which could save the company around $12 million annually in interest.

Tenet Healthcare, another AI-selected stock, showcased impressive gains as well. The company's second-quarter results, announced on July 23, saw revenue rise 6.8% to $5.628 billion and adjusted EBITDA increase 16.3% to $1.304 billion. Tenet's ambulatory care business played a crucial role in this success. The company repurchased 5.68 million shares for $1.042 billion in the second quarter alone.

However, exchange-related revenue fell 17% in the quarter, and Tenet's investments are susceptible to policy changes involving Affordable Care Act subsidies, which remain unpredictable for quantitative models.

The third and final AI-selected stock was Mettler-Toledo, added to the portfolio on September 1. The stock closed at $1,684.64 on Thursday, a 22.43% gain since selection, including a 13.74% increase this month. The model recognized Mettler-Toledo as a high-quality compounder whose shares had become undervalued. The company's second-quarter sales rose 7% to $1.03 billion, and adjusted earnings per share increased by 14% to $11.46.

Management raised full-year adjusted earnings guidance to $47.15-$47.50 a share, with expected growth between 10% and 11%, compared to the previous 8% to 10% outlook. The stock is, however, valued at roughly 36 times the midpoint of its full-year earnings guidance.